INTERVENTION 1:	Intervention	0
Eribulin Mesylate	Intervention	1
eribulin mesylate	CHEBI:70710	0-17
The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate	Intervention	2
eribulin mesylate	CHEBI:70710	33-50
eribulin mesylate	CHEBI:70710	240-257
week	UO:0000034	174-178
week	UO:0000034	182-186
week	UO:0000034	203-207
Eribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.	Intervention	3
eribulin mesylate	CHEBI:70710	0-17
eribulin mesylate	CHEBI:70710	44-61
MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate	Intervention	4
week	UO:0000034	33-37
week	UO:0000034	41-45
week	UO:0000034	62-66
eribulin mesylate	CHEBI:70710	99-116
Pre-Medication: Zofran: Zofran at 8mg orally. Given at the discretion of the treating physician	Intervention	5
Pre-Medication: Decadron: decadron at 8mg orally. Given at the discretion of the treating physician	Intervention	6
Inclusion Criteria:	Eligibility	0
Female with histologically confirmed breast cancer.	Eligibility	1
female	PATO:0000383	0-6
breast cancer	DOID:1612	37-50
Patients must have evidence of metastatic disease (non measurable disease is eligible).	Eligibility	2
disease	DOID:4,OGMS:0000031	42-49
disease	DOID:4,OGMS:0000031	66-73
Radiologically confirmed metastatic brain lesion by MRI.	Eligibility	3
brain	UBERON:0000955	36-41
Brain metastases from breast cancer with or without prior WBRT, STS of surgical resection. Progression must be documented in an at least one lesion untreated by SRS or in any site after surgery or WBRT.	Eligibility	4
brain	UBERON:0000955	0-5
breast cancer	DOID:1612	22-35
site	BFO:0000029	175-179
surgery	OAE:0000067	186-193
Patients must be neurologically stable and with stable dose steroids and anticonvulsants for at least 1 week prior to obtaining the baseline MRI of the brain, and/or at least 1 week prior to beginning study treatment.	Eligibility	5
stable	HP:0031915	32-38
stable	HP:0031915	48-54
week	UO:0000034	104-108
week	UO:0000034	177-181
brain	UBERON:0000955	152-157
No presence of uncontrolled systemic disease or tumor related complication which, in opinion of the investigator, might restrict life expectancy to less than 3 months.	Eligibility	6
disease	DOID:4,OGMS:0000031	37-44
Patients may not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during protocol treatment. Trastuzumab is allowed in HER2 positive patients).	Eligibility	7
breast cancer	DOID:1612	76-89
Able to comprehend and willing to sign an Informed Consent Form (ICF)	Eligibility	8
Karnofsky performance status  60	Eligibility	9
No brain radiation therapy > 4 weeks	Eligibility	10
brain	UBERON:0000955	3-8
No chemotherapy for > 3 weeks before planned start of protocol treatment	Eligibility	11
Adequate bone marrow, renal, and hepatic function, per local reference laboratory ranges as follows:	Eligibility	12
bone marrow	UBERON:0002371	9-20
function	BAO:0003117,BFO:0000034	41-49
Absolute neutrophil count (ANC)  1,500/mm3	Eligibility	13
Platelet count  100,000/mm3	Eligibility	14
platelet count	CMO:0000029	0-14
Hemoglobin  9 g/dL	Eligibility	15
hemoglobin	CHEBI:35143	0-10
Calculated creatinine clearance (CrCl)  30mL/min (Cockcroft-Gault method)	Eligibility	16
creatinine clearance	CMO:0000765	11-31
Patients with normal, mild or moderate hepatic dysfunction are eligible.	Eligibility	17
mild	HP:0012825	22-26
moderate	HP:0012826	30-38
Calcium <10.1 mg/dL (corrected to serum albumin as follows: Corrected Calcium = (0.8 x (4 - patient albumin)) + serum Ca	Eligibility	18
calcium	CHEBI:22984,BAO:0000874	0-7
calcium	CHEBI:22984,BAO:0000874	70-77
serum albumin	BAO:0002066	34-47
x	LABO:0000148	85-86
patient	HADO:0000008,OAE:0001817	92-99
Females of child-bearing potential must have a negative pregnancy test at screening and agree to take appropriate precautions to avoid pregnancy (double barrier method of birth control or abstinence) from screening through 3 months after the last dose of treatment	Eligibility	19
Able to undergo MRI evaluation with and without gadolinium contrast	Eligibility	20
Exclusion Criteria:	Eligibility	21
Patients with the presence of an active infection, abscess or fistula	Eligibility	22
active	PATO:0002354	33-39
abscess	HP:0025615	51-58
Known leptomeningeal disease or CNS midline shifts.	Eligibility	23
disease	DOID:4,OGMS:0000031	21-28
Any evidence of severe or uncontrolled systemic disease such as clinically significant cardiovascular, pulmonary, hepatic, renal or metabolic disease.	Eligibility	24
severe	HP:0012828	16-22
disease	DOID:4,OGMS:0000031	48-55
disease	DOID:4,OGMS:0000031	142-149
Severe conduction abnormality including significant QTc prolongation >450ms.	Eligibility	25
severe	HP:0012828	0-6
Patients with grade 3/4 peripheral neuropathy.	Eligibility	26
peripheral neuropathy	HP:0009830,DOID:870	24-45
Patients with pacemaker or an ICD devices.	Eligibility	27
Previous treatment with eribulin mesylate.	Eligibility	28
eribulin mesylate	CHEBI:70710	24-41
Outcome Measurement:	Results	0
Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS)	Results	1
percent	UO:0000187	0-7
central nervous system	UBERON:0001017	29-51
The study team will assess the percent of participants without CNS progression at 3 months. The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS. Response and progression by MR were evaluated using WHO/modified McDonald's criteria.	Results	2
percent	UO:0000187	31-38
Time frame: At 12 weeks	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Eribulin Mesylate	Results	5
eribulin mesylate	CHEBI:70710	17-34
Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate	Results	6
eribulin mesylate	CHEBI:70710	56-73
eribulin mesylate	CHEBI:70710	263-280
week	UO:0000034	197-201
week	UO:0000034	205-209
week	UO:0000034	226-230
Eribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.	Results	7
eribulin mesylate	CHEBI:70710	0-17
eribulin mesylate	CHEBI:70710	44-61
MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate	Results	8
week	UO:0000034	33-37
week	UO:0000034	41-45
week	UO:0000034	62-66
eribulin mesylate	CHEBI:70710	99-116
Pre-Medication: Zofran: Zofran at 8mg orally. Given at the discretion of the treating physician	Results	9
Pre-Medication: Decadron: decadron at 8mg orally. Given at the discretion of the treating physician	Results	10
Overall Number of Participants Analyzed: 9	Results	11
Measure Type: Number	Results	12
Unit of Measure: percentage of participants  88.9        (51 to 99.7)	Results	13
Adverse Events 1:	Adverse Events	0
Total: 3/9 (33.33%)	Adverse Events	1
Febrile neutropenia * 1/9 (11.11%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Fatigue * 1/9 (11.11%)	Adverse Events	3
fatigue	HP:0012378	0-7
Lung infection * 1/9 (11.11%)	Adverse Events	4
lung	UBERON:0002048	0-4
Neutrophil count decreased * 1/9 (11.11%)	Adverse Events	5
Platelet count decreased * 1/9 (11.11%)	Adverse Events	6
platelet count	CMO:0000029	0-14
White blood cell decreased * 1/9 (11.11%)	Adverse Events	7
blood	UBERON:0000178	6-11
Pain in extremity * 1/9 (11.11%)	Adverse Events	8
pain	HP:0012531	0-4
worsening pseudomeningeocele * 1/9 (11.11%)	Adverse Events	9
Dyspnea * 1/9 (11.11%)	Adverse Events	10
dyspnea	HP:0002094	0-7
Thromboembolic event * 1/9 (11.11%)	Adverse Events	11
